Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Guzzi

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Minerva Chirurgica|October 31, 1981
[Multiple non-parasitic cysts of the liver. Diagnostic considerations. Clinical case report]F Donadio, M Guzzi Susini, V La Ganga, et al.
Journal of Medicinal Chemistry|May 4, 2001
Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90)A Balasubramaniam, V C Dhawan, D E Mullins, et al.
Peptides|May 4, 2000
[D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intakeE M Parker, A Balasubramaniam, M Guzzi, et al.
Physical Review Letters|May 17, 2012
Optical spin injection and spin lifetime in Ge heterostructuresF Pezzoli, F Bottegoni, D Trivedi, et al.
European Journal of Pharmacology|July 21, 1998
GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonistsE M Parker, C K Babij, A Balasubramaniam, et al.
Critical Care (London, England)|June 22, 2019
Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panelLouis M Guzzi, Tobias Bergler, Brian Binnall, et al.
Critical Care Explorations|August 24, 2023
Feasibility Assessment of a Biomarker-Guided Kidney-Sparing Sepsis Bundle: The Limiting Acute Kidney Injury Progression In Sepsis TrialHernando Gómez, Alexander Zarbock, Stephen M Pastores, et al.
Neuropharmacology|May 31, 2011
The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodentsP H Hutson, E N Finger, B C Magliaro, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Minerva Chirurgica|October 31, 1981
[Multiple non-parasitic cysts of the liver. Diagnostic considerations. Clinical case report]F Donadio, M Guzzi Susini, V La Ganga, et al.
Journal of Medicinal Chemistry|May 4, 2001
Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90)A Balasubramaniam, V C Dhawan, D E Mullins, et al.
Peptides|May 4, 2000
[D-Trp(34)] neuropeptide Y is a potent and selective neuropeptide Y Y(5) receptor agonist with dramatic effects on food intakeE M Parker, A Balasubramaniam, M Guzzi, et al.
Physical Review Letters|May 17, 2012
Optical spin injection and spin lifetime in Ge heterostructuresF Pezzoli, F Bottegoni, D Trivedi, et al.
European Journal of Pharmacology|July 21, 1998
GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonistsE M Parker, C K Babij, A Balasubramaniam, et al.
Critical Care (London, England)|June 22, 2019
Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panelLouis M Guzzi, Tobias Bergler, Brian Binnall, et al.
Critical Care Explorations|August 24, 2023
Feasibility Assessment of a Biomarker-Guided Kidney-Sparing Sepsis Bundle: The Limiting Acute Kidney Injury Progression In Sepsis TrialHernando Gómez, Alexander Zarbock, Stephen M Pastores, et al.
Neuropharmacology|May 31, 2011
The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodentsP H Hutson, E N Finger, B C Magliaro, et al.
Pageof 2